Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies.
Combining two common diabetes drugs significantly reduces death and hospitalization in heart failure patients compared to using one drug alone.
In the largest observational meta-analysis to date (n=75,833 heart failure patients, PROSPERO-registered), combined GLP-1 receptor agonist and SGLT2 inhibitor therapy significantly reduced all-cause mortality (RR 0.62), all-cause hospitalization (RR 0.89), and worsening heart failure (RR 0.74) compared to SGLT2 inhibitor monotherapy. These findings support consideration of combination therapy in heart failure management, pending confirmatory randomized trials.
What the study was
- Study design
- systematic review and meta-analysis of observational cohort studies
- Population
- Heart failure patients, meta-analysis (n=75,833)
- Sample size
- 75833
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- American journal of cardiovascular drugs
Why it surfaced
Largest observational meta-analysis (n=75,833, PROSPERO-registered) quantifying clinical benefit of GLP-1 RA + SGLT2i combination in established HF; moderate GRADE evidence with directly actionable magnitude; fills evidence gap ahead of RCTs.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.